Catcha Investment Corp - Ordinary Shares (CHAA) 10-Q 18 Aug 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Aug. 18, 2023
Document Information Line Items
Entity Registrant Name	CATCHA INVESTMENT CORP
Trading Symbol	CHAA
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001838293
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40061
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	98-1574476
Entity Address, Address Line One	Level 42, Suntec Tower Three
Entity Address, City or Town	8 Temasek Blvd
Entity Address, Country	SG
Entity Address, Postal Zip Code	038988
City Area Code	+65
Local Phone Number	6829-2294
Title of 12(b) Security	Class A ordinary shares, par value $0.0001 per share
Security Exchange Name	NYSEAMER
Entity Interactive Data Current	Yes
Class A Ordinary Shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		2,214,859
Class B Ordinary Shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		7,500,000

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Assets
Cash	$ 115,597	$ 20,706
Prepaid expenses	77,973	33,875
Total current assets	193,570	54,581
Cash and investments held in Trust Account	23,276,408	304,086,289
Total Assets	23,469,978	304,140,870
Liabilities and Shareholders’ Deficit
Accounts payable and accrued expenses	1,139,803	599,443
Due to Related Party	155,625	125,625
Promissory Note - Related Party, at fair value	58,044
Working Capital Loan, at fair value	107,795
Capital Contribution Note, at fair value	1,308,748
Total current liabilities	2,770,015	725,068
Warrant liability	181,169	68,660
Deferred underwriting fees	10,500,000	10,500,000
Total liabilities	13,451,184	11,293,728
Commitments and Contingencies (Note 8)
Class A ordinary shares subject to possible redemption, 2,214,859 and 30,000,000 shares at redemption value of $10.51 and $10.14 per share as of March 31, 2023 and December 31, 2022, respectively	23,276,408	304,086,289
Shareholders’ Deficit:
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no shares issued and outstanding (excluding 2,214,859 and 30,000,000 shares subject to possible redemption, respectively) at March 31, 2023 and December 31, 2022
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 7,500,000 shares issued and outstanding at March 31, 2023 and December 31, 2022	750	750
Additional paid-in capital
Accumulated deficit	(13,258,364)	(11,239,897)
Total shareholders’ deficit	(13,257,614)	(11,239,147)
Total Liabilities and Shareholders’ Deficit	$ 23,469,978	$ 304,140,870

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Ordinary shares subject to possible redemption	2,214,859	30,000,000
Ordinary shares subject to possible redemption, redemption value (in Dollars per share)	$ 10.51	$ 10.14
Preferred stock par or stated value per share (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued
Preferred stock shares outstanding
Class A Ordinary Shares
Common stock par or stated value per share (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued
Common stock shares outstanding
Class B Ordinary Shares
Common stock par or stated value per share (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock shares authorized	50,000,000	50,000,000
Common stock shares issued	7,500,000	7,500,000
Common stock shares outstanding	7,500,000	7,500,000

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Formation and operating costs	$ 909,935	$ 390,883
Loss from operations	(909,935)	(390,883)
Other income (expense):
Interest income from Trust Account	1,943,762	37,518
Excess of fair value of Capital Contribution Note over proceeds at issuance	(1,104,618)
Change in fair value of Convertible Promissory Notes	(901)
Change in fair value of Capital Contribution Note	(4,130)
Change in fair value of warrant liability	(112,509)	5,069,115
Total other income (expense), net	721,604	5,106,633
Net (loss) income	$ (188,331)	$ 4,715,750
Redeemable Class A ordinary shares
Other income (expense):
Basic weighted average shares outstanding (in Shares)	16,724,877	30,000,000
Basic net income per share (in Dollars per share)	$ (0.01)	$ 0.13
Non-redeemable Class B ordinary shares
Other income (expense):
Basic weighted average shares outstanding (in Shares)	7,500,000	7,500,000
Basic net income per share (in Dollars per share)	$ (0.01)	$ 0.13

Unaudited Condensed Statement_2

Unaudited Condensed Statements of Operations (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Redeemable Class A ordinary shares
Diluted weighted average shares outstanding	16,724,877	30,000,000
Diluted net income per share	$ 0.01	$ 0.13
Non-redeemable Class B ordinary shares
Diluted weighted average shares outstanding	7,500,000	7,500,000
Diluted net income per share	$ 0.01	$ 0.13

Unaudited Condensed Statement o

Unaudited Condensed Statement of Changes in Shareholders’ Deficit - USD ($)	Class A Ordinary Shares	Class B Ordinary Shares	Additional Paid-in Capital	Accumulated Deficit	Total
Balance (in Shares) at Dec. 31, 2021		7,500,000
Balance at Dec. 31, 2021		$ 750		$ (18,854,567)	$ (18,853,817)
Net income (loss)				4,715,750	4,715,750
Accretion of interest income to Class A shares subject to redemption				(37,518)	(37,518)
Balance at Mar. 31, 2022		$ 750		(14,176,335)	(14,175,585)
Balance (in Shares) at Mar. 31, 2022		7,500,000
Balance (in Shares) at Dec. 31, 2022		7,500,000
Balance at Dec. 31, 2022		$ 750		(11,239,897)	(11,239,147)
Net income (loss)				(188,331)	(188,331)
Accretion of interest income to Class A shares subject to redemption				(1,943,762)	(1,943,762)
Excess of proceeds from convertible notes over fair value at issuance				263,626	263,626
Additional deposits to Trust Account for extension				(150,000)	(150,000)
Balance at Mar. 31, 2023		$ 750		$ (13,258,364)	$ (13,257,614)
Balance (in Shares) at Mar. 31, 2023		7,500,000

Unaudited Condensed Statement_3

Unaudited Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows from Operating Activities:
Net (loss) income	$ (188,331)	$ 4,715,750
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Interest income from Trust Account	(1,943,762)	(37,518)
Excess of fair value of Capital Contribution Note over proceeds at issuance	1,104,618
Change in fair value of warrant liability	112,509	(5,069,115)
Change in fair value of convertible promissory notes	901
Change in fair value of Capital Contribution Note	4,130
Changes in current assets and current liabilities:
Prepaid expenses	(44,098)	35,876
Accounts payable and accrued expenses	540,360	4,187
Due to related party	30,000	29,625
Net cash used in operating activities	(383,673)	(321,195)
Cash Flows from Investing Activities:
Cash deposited in Trust Account	(150,000)
Cash withdrawn from Trust Account in connection with redemption	282,903,643
Net cash provided by investing activities	282,753,643
Cash Flows from Financing Activities:
Proceeds from issuance of Working Capital Loan	278,564
Proceeds from issuance of promissory note to related party	150,000
Proceeds from issuance of capital contribution note	200,000
Redemption of Class A ordinary shares	(282,903,643)
Net cash used in financing activities	(282,275,079)
Net Change in Cash	94,891	(321,195)
Cash - Beginning of the period	20,706	995,064
Cash - End of the period	115,597	673,869
Supplemental Disclosure of Non-cash Financing Activities:
Accretion of interest income to Class A shares subject to possible redemption	1,943,762	37,518
Accretion of extension deposits to Class A shares subject to possible redemption	150,000
Excess of proceeds from convertible notes over fair value at issuance	$ 263,626

Organization and Business Opera

Organization and Business Operation	3 Months Ended
	Mar. 31, 2023
Organization and Business Operation [Abstract]
ORGANIZATION AND BUSINESS OPERATION	NOTE 1. ORGANIZATION AND BUSINESS OPERATION Organization and General Catcha Investment Corp (the “Company”) was incorporated as a Cayman Islands exempted company on December 17, 2020. The Company was incorporated for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of March 31, 2023, the Company had not commenced any operations. All activity through March 31, 2023 relates to the Company’s formation, the initial public offering, and after the initial public offering, searching for a Business Combination target. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and investments held in Trust Account from the proceeds derived from the initial public offering and will recognize changes in the fair value of warrant liability and convertible promissory notes as other income (expense). The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Catcha Holdings LLC, a Cayman Islands limited liability company (the “Sponsor”). Financing The registration statement for the Company’s Initial Public Offering (as defined below) was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 11, 2021 (the “Effective Date”). On February 17, 2021, the Company consummated the initial public offering (the “Initial Public Offering” or “IPO”) of 30,000,000 units (the “Units” and, with respect to the Class A ordinary share included in the Units sold, the “Public Shares”), including the issuance of 2,500,000 Units as a result of the underwriters’ partial exercise of the over-allotment, at $10.00 per Unit generating gross proceeds of $300,000,000, which is described in Note 3. Each Unit consists of one Class A ordinary share, and one-third of one warrant to purchase one Class A ordinary share. Each whole warrant will entitle the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Each whole warrant will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO, February 17, 2021, and will expire five years after the completion of the initial Business Combination, or earlier upon redemption or liquidation (see Note 3). Simultaneously with the closing of the IPO, the Company consummated the sale of an aggregate of 5,333,333 warrants (the “Private Placement Warrants”) at a price of $1.50 per warrant in a private placement to the Company’s Sponsor, generating gross proceeds to the Company of $8,000,000, which is described in Note 4. Following the closing of the IPO on February 17, 2021, an amount of $300,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”) and was invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act that invests only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the Company’s second amended and restated memorandum and articles of association, and subject to the requirements of law and regulation, will provide that the proceeds from the IPO held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the Company’s public shareholders, until the earliest of (i) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s second amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of its Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company does not complete the initial Business Combination within 24 months from the closing of the IPO (the “Combination Period”) or during any extended time in which the Company has to consummate a Business Combination beyond the aforementioned period as a result of a shareholder vote to amend the second amended and restated memorandum and articles of association (an “Extension Period”) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares, and (iii) the redemption of the Company’s public shares if the Company has not consummated its Business Combination within the Combination Period, subject to applicable law. Transaction costs amounted to $17,031,183, consisting of $6,000,000 of underwriting fees, $10,500,000 of deferred underwriting fees (see Note 7), and $531,183 of other offering costs. Of the $17,031,183 transaction costs, $16,236,137 was charged to additional paid-in capital and $795,046 was allocated to the public and private warrants and recorded as other income (loss) during the three months ended March 31, 2021. On August 10, 2023, J.P. Morgan waived its entitlement to the payment of $10,500,000 deferred underwriting fee in connection with its role as underwriter in the Company’s IPO. Furthermore, J.P. Morgan had no role in connection with the business combination transaction. Initial Business Combination The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting discount) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”). The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of the initial Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then outstanding public shares. The amount in the Trust Account was initially $10.00 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in the case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. On February 14, 2023, the Company held an extraordinary general meeting of shareholders (the “Extraordinary General Meeting”). At the Extraordinary General Meeting, the Company’s shareholders approved i) an amendment to the Company’s amended and restated memorandum and articles of association (the “Extension Amendment”) to extend the date by which the Company has to consummate a business combination from February 17, 2023 to the Extended Date described below (the “Extension Amendment Proposal”), ii) a proposal (the “Trust Amendment Proposal”) to amend the Company’s investment management trust agreement, dated as of February 11, 2021 (the “IMTA”), by and between the Company and Continental Stock Transfer Company (“CST”), to extend the date by which the Company has to consummate a business combination from February 17, 2023 to February 17, 2024 or such earlier date as is determined by the Company’s board of directors (such date, the “Extended Date”). Following such approval by the Company’s shareholders, the Company and CST entered into the Amendment No. 1 to the IMTA on February 14, 2023 (the “IMTA Amendment”). In connection with the vote to approve the Articles Amendment, holders of 27,785,141 Class A ordinary shares of the Company properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.18 per share, for an aggregate redemption amount of $282,903,643. The funds were redeemed from the Trust Account on February 23, 2023. On February 22, 2023, March 21, 2023, April 19, 2023, May 19, 2023, June 20, 2023 and July 20, 2023, the Company deposited six tranches of $75,000, for an aggregate of $450,000, into the Trust Account, to extend the date that the Company has to consummate a business combination from February 17, 2023 to August 17, 2023. The Company has 3 business days after August 17, 2023 to deposit another $75,000 to the Trust Account, to extend the date that the Company has to consummate a business combination to September 17, 2023. The Company will make such deposit shortly after the condensed financial statements are issued. The Company will be required to make further monthly deposits of $75,000 to extend this date for each month up through February 17, 2024. The Company is under no further obligation to make any additional deposits. The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their Founder Shares in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s second amended and restated memorandum and articles of association, and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate the initial Business Combination within the Combination Period or during any Extension Period. The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay the Company’s tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. Business Combination Agreement On August 3, 2023, the Company entered into a Business Combination Agreement (the “Business Combination Agreement”) with Crown LNG Holdings AS, a private limited liability company incorporated under the laws of Norway (“Crown”), Crown LNG Holdings Limited, a private limited company incorporated under the laws of Jersey, Channel Islands (“PubCo”), and CGT Merge II Limited, a Cayman Islands exempted company limited by shares (“Merger Sub”). Pursuant to the Business Combination Agreement, subject to the satisfaction or waiver of certain conditions set forth therein, (i) Merger Sub will merge with and into the Company, with the Company being the surviving company and becoming the wholly owned subsidiary of PubCo, as a result of which (a) each the Company Class A Ordinary Share and each Class B Ordinary Share issued and outstanding immediately prior to the effective of the merger (the “Merger Effective Time”) shall automatically be cancelled and cease to exist in exchange for the right to receive one newly issued share of PubCo common stock, and (b) each the Company Warrant outstanding immediately prior to the Merger Effective Time shall cease to be a warrant with respect to the Company Ordinary Shares and be assumed by PubCo and converted into a warrant to purchase one share of PubCo common stock; and (ii) subject to the certain procedures and conditions, Crown shareholders will transfer their Crown stock to PubCo in exchange for their Pro Rata Share (as defined below) of the Exchange Consideration, and the Exchange Consideration is a number of shares of PubCo Common Stock issued by PubCo equal to (a) a transaction value of $600 million (the “Transaction Value”) divided by (b) a per share price of $10.00. Pro Rata Share means with respect to each Crown shareholder, a fraction expressed as a percentage equal to (i) the number of shares of Crown stock held by such Crown shareholder immediately prior to the effective of the exchange (the “Exchange Effective Time”), divided by (ii) the total number of issued and outstanding shares of Company Stock immediately prior to the Exchange Effective Time. During the seven years following the consumption of the Business Combination (the “Closing”), the persons who are Crown shareholders immediately prior to the Exchange Effective Time and who have participated in the Exchange (the “Exchanging Shareholders”) shall have the contingent right to receive in the aggregate a number of shares of PubCo Common Stock equivalent to 10% of the issued and outstanding PubCo Common Stock as of the Closing, which will vest upon achievement of certain share prices and milestones as provided under the Business Combination Agreement. The Business Combination Agreement may be terminated under certain customary circumstances at any time prior to the Closing, including, without limitation, (i) upon the mutual written consent of the Company and Crown, (ii) by either the Company or Crown, if any of the conditions to the Closing has not been satisfied or waived by February 17, 2024, (iii) by the Company, on the one hand, or Crown, on the other hand, as a result of certain material breaches by the counterparties to the Business Combination Agreement that remain uncured after any applicable cure period, (iv) by either the Company or Crown, if a governmental authority of competent jurisdiction shall have issued an order or taken any other action permanently prohibiting the transactions contemplated by the Business Combination Agreement, (v) by the Company, on the one hand, or Crown, on the other hand, as a result of the failure by the counterparties to obtain approvals required for the Business Combination, (vi) by the Company, if there has been a material adverse effect on each of the Crown and its direct and indirect subsidiaries and (vii) by the Company, if the Crown’s financials have not been delivered to the Company by September 15, 2023. Going Concern As of March 31, 2023, the Company had $115,597 in cash outside of the Trust Account and working capital deficit of $2,576,445. On December 13, 2022, the Company issued an unsecured convertible promissory note (see Note 5) to the Sponsor, pursuant to which the Company may borrow up to $1,500,000 (the “Convertible Promissory Note”) from the Sponsor. As of March 31, 2023, the Company has $278,564 outstanding under such loan. Up to the date that the condensed financial statements were issued, the Company received a total of $ 578,564 On February 14, 2023, the Company issued an unsecured convertible promissory note (the “Extension Note”) to the Sponsor, pursuant to which the Company may borrow up to $900,000 (the “Extension Loan”) from the Sponsor. Pursuant to the Extension Note, from February 17, 2023 to February 17, 2024 or such earlier date as is determined by the Company’s board of directors (such date, the “Extended Date”), the Sponsor has agreed to deposit into the Company’s Trust Account established in connection with its IPO the lesser of (i) $75,000 or (ii) $0.0375 for each unredeemed public share, for each month (or a pro rata portion thereof if less than a month) until the earlier of (i) the date of the extraordinary general meeting held in connection with a shareholder vote to approve an initial Business Combination, and (ii) the date that $900,000 has been loaned. As of March 31, 2023, the Company has $150,000 outstanding under such loan. Up to the date that the condensed financial statements were issued, the Company had received $450,000 under the Extension Loan. Using these loans received, the Company deposited six tranches of $75,000 into Trust Account on February 22, 2023, March 21, 2023, April 19, 2023, May 19, 2023, June 20, 2023 and July 20, 2023, to extend the date that the Company has to consummate a business combination from February 17, 2023 to August 17, 2023. The Company has 3 business days after August 17, 2023 to deposit another $75,000 to the Trust Account, to extend the date that the Company has to consummate a business combination to September 17, 2023. The Company will make such deposit shortly after the condensed financial statements are issued. The Company will be required to make further monthly deposits of $75,000 to extend this date for each month up through February 17, 2024. The Company is under no further obligation to make any additional deposits. On March 9, 2023, the Company entered into a subscription agreement (the “Subscription Agreement”) with the Sponsor and Polar Multi-Strategy Master Fund (the “Investor” or “Polar”), pursuant to which, the Investor has agreed to provide $300,000 to the Company (the “Capital Contribution Note”, See Note 6). As of March 31, 2023, the Company has $200,000 outstanding under such loan. On May 24, 2023, the Company received the remaining $100,000 from Polar. Up to the date that the condensed financial statements were issued, the Company has received the entire $300,000 in total funding from Polar (see Note 6). In addition to the $1,500,000 Convertible Promissory Note (as defined in Note 2), in order to fund working capital deficiencies or finance transaction costs in connection with a business combination, our sponsor, or certain of the Company’s officers and directors or their affiliates may, but are not obligated to, loan the Company funds as may be required. Management will use these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating a Business Combination. No additional funding has been received under this arrangement. However, management expects the Company to continue to incur significant costs in pursuit of the consummation of a Business Combination and current funds, committed or otherwise, may not be sufficient to operate the Company for at least the 12 months following the issuance of the unaudited condensed financial statements contained herein. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Subtopic (“ASC”) 205-40, “Presentation of Financial Statements – Going Concern,” management has determined that if the Company is unable to complete a Business Combination by February 17, 2024 or such earlier date as is determined by the Company’s board of directors, then the Company will cease all operations except for the purpose of liquidating. The mandatory liquidation, subsequent dissolution and the liquidity issues described above raise substantial doubt about the Company’s ability to continue as a going concern one year from the date that these condensed financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to continue as a going concern. Risks and Uncertainties Management is currently evaluating the impact of the COVID-19 pandemic and Russia-Ukraine war and has concluded that while it is reasonably possible that the virus and war could have a negative effect on the Company’s financial position, results of its operations and/or closing a business combination, the specific impact is not readily determinable as of the date of the condensed financial statements. The accompanying unaudited condensed financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the period presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on April 24, 2023, which the accompanying condensed balance sheet as of December 31, 2022 was derived from. The interim results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods. Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply on on-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of the condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $115,597 and $20,706 in cash and did not have any cash equivalents as of March 31, 2023 and December 31, 2022, respectively. Cash and investments held in Trust Account In March 2023, the Company liquidated the money market funds held in the Trust Account. The funds in the Trust Account will be maintained in cash in an interest-bearing demand deposit account at a bank until the earlier of consummation of the initial Business Combination and liquidation. Prior to liquidating the money market funds, the Company’s portfolio of investments was comprised primarily of U.S. Treasury securities. The Company classifies its money market funds as trading securities in accordance with ASC Topic 320, “Investments-Debt and Equity Securities.” Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from Trust Account in the accompanying unaudited condensed statements of operations. As of March 31, 2023 and December 31, 2023, the assets held in the Trust Account were $23,276,408 and $304,086,289, respectively. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At March 31, 2023 and December 31, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value Measurements FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”) defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: ● Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. ● Level 2 - Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. ● Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value of certain of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, approximates the carrying amounts represented in the condensed balance sheets. The fair values of prepaid expenses, accounts payable and accrued expenses, and due to related party are estimated to approximate the carrying values as of March 31, 2023 and December 31, 2022 due to the short maturities of such instruments. Offering Costs Associated with IPO The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A-“Expenses of Offering”. Offering costs consist principally of underwriting fees, professional and registration fees that are related to the IPO. FASB ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between Class A ordinary shares and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then the Class A ordinary shares. Offering costs in the aggregate of $16,236,137 have been charged to shareholders’ equity (deficit) (consisting of $5,724,193 in underwriting fees, plus $10,017,338 in deferred underwriting fees, and $494,606 of other offering costs), offering costs in the aggregate of $795,046 have been recorded as other income (loss) (consisting of $275,807 in underwriting fees, plus $482,662 in deferred underwriting fees, and $36,577 of other offering costs) during the three months ended March 31, 2021. Over-allotment Option Liability The Company accounted for the over-allotment option in accordance with the guidance contained in ASC 815-40. The over-allotment is not considered indexed to the Company’s own ordinary shares, and as such, it does not meet the criteria for equity treatment and is recorded as liabilities. On February 17, 2021, the underwriters exercised the over-allotment option partially and the remaining was expired on March 28, 2021. The fair value changes of over-allotment option liability between IPO closing date and the expiration date were recorded in operations during the year ended December 31, 2021. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in FASB ASC Topic 480, “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, all ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s condensed balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. In connection with the Extraordinary General Meeting held on February 14, 2023, holders of 27,785,141 Class A ordinary shares of the Company properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.18 per share, for an aggregate redemption amount of $282,903,643, which includes interest of $5,052,233. At March 31, 2023 and December 31, 2022, the Class A ordinary shares reflected in the condensed balance sheets are reconciled in the following table: Shares Amount Gross proceeds from initial public offering 30,000,000 $ 300,000,000 Less: Proceeds allocated to Public Warrants - (13,790,354 ) Less: Class A ordinary shares issuance costs - (16,236,137 ) Less: Initial fair value of over-allotment option - (325,679 ) Add: Remeasurement of Class A ordinary shares to redemption value - 30,352,170 Add: Accretion of interest income to Class A shares subject to redemption - 4,086,289 Class A ordinary shares subject to possible redemption as of December 31, 2022 30,000,000 304,086,289 Add: Accretion of interest income to Class A shares subject to redemption - 1,943,762 Add: Accretion of extension deposit to Class A shares subject to redemption - 150,000 Less: Class A shares redeemed, including interest (27,785,141 ) (282,903,643 ) Class A ordinary shares subject to possible redemption as of March 31, 2023 2,214,859 $ 23,276,408 Convertible Promissory Notes The Company elected to account for the Convertible Promissory Notes (which include the $1.5 million Convertible Promissory Note and the Extension Note) entered into with Catcha Holdings LLC (“Sponsor”) pursuant to the fair value option under ASC 825. ASC 825-10-15-4 provides for the “fair value option” (“FVO”) election, to the extent not otherwise prohibited by ASC 825-10-15-5, to be afforded to financial instruments, wherein the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Differences between the face value of the convertible promissory note and fair value at issuance are recognized as either an expense in the statement of operations (if issued at a premium) or as a capital contribution (if issued at a discount). Any material changes in the estimated fair value of the convertible promissory note are recognized as non-cash gains or losses in the condensed statements of operations. The Company believes that the fair value option better reflects the underlying economics of the Convertible Promissory Notes. As such, the Convertible Promissory Notes, were initially measured at $164,938 as of the issue date (including $107,128 under $1.5 Million Convertible Promissory Note and $57,810 under the Extension Note). The $263,626 excess of proceeds over fair value at issuance was recorded as additional paid-in capital in the accompanying unaudited condensed statements of shareholders’ deficit for the three months ended March 31, 2023. As of March 31, 2023, the fair value of the Convertible Promissory Notes was $165,839 (including $107,795 under $1.5 Million Convertible Promissory Note and $58,044 under the Extension Note). For the three months ended March 31, 2023, the Company recognized $901 unrealized loss on fair value changes of the Convertible Promissory Notes, in the unaudited condensed statement of operations. Capital Contribution Note The Company elected to account for the Capital Contribution Note entered into with Polar Multi-Strategy Master Fund (“Investor”) and Catcha Holdings LLC (“Sponsor”) pursuant to the fair value option under ASC 825. ASC 825-10-15-4 provides for the “fair value option” (“FVO”) election, to the extent not otherwise prohibited by ASC 825-10-15-5, to be afforded to financial instruments, wherein the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Differences between the face value of the Capital Contribution Note and fair value at issuance are recognized as either an expense in the statement of operations (if issued at a premium) or as a capital contribution (if issued at a discount). Any material changes in the estimated fair value of the Capital Contribution Note are recognized as non-cash gains or losses in the condensed statements of operations. The Company believes that the fair value option better reflects the underlying economics of the Capital Contribution Note. The fair value of the Capital Contribution Note will include both the fair value of the 300,000 shares in consideration for the Capital Calls as defined in Note 6 and the principal as of each reporting date. As such, the Capital Contribution Note, was initially measured at $1,304,618 as of the issue date. The $1,104,618 excess of fair value of Capital Contribution Note over proceeds at issuance was recorded in the accompanying unaudited condensed statement of operations for the three months ended March 31, 2023. As of March 31, 2023, the fair value of the Capital Contribution Note was $1,308,748. For the three months ended March 31, 2023, the Company recognized $4,130 unrealized loss on fair value changes of the Capital Contribution Note, in the unaudited condensed statements of operations. Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the warrants issued in connection with the IPO and the Private Placement in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classified each warrant as a liability at its fair value. This liability is subject to re-measurement at each reporting periods. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. As of March 31, 2023 and December 31, 2022, there were 15,333,333 public and private warrants outstanding (not including the 285,409 warrants that could be issued upon conversion of the Convertible Promissory Notes). Net Income (Loss) Per Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 15,333,333 potential common shares for outstanding warrants to purchase the Company’s stock, the 285,709 potential common shares for the warrants that could be issued upon conversion of the Convertible Promissory Notes, to purchase the Company’s stock, and the 320,000 potential common shares (including 20,000 shares for the Business Combination Payment if Polar elects so and 300,000 shares in consideration of the Capital Calls as described in Note 6) that will be issued to Polar at Business Combination closing were excluded from diluted earnings per share for the three months ended March 31, 2023 and 2022 because the warrants and the shares that will be issued to Polar are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods. In addition, any shares subject to forfeiture are not included in weighted average shares outstanding until the forfeiture restrictions lapse. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares. Because the redemption value of the Class A ordinary shares approximates their fair value, remeasurement to redemption value is not impacting allocable earnings. For the Three Months Ended March 31, 2023 2022 Class A Class B Class A Class B Basic and diluted net income per share: Numerator: Allocation of net income (loss) $ (130,024 ) $ (58,307 ) $ 3,772,600 $ 943,150 Denominator: Weighted-average shares outstanding 16,724,877 7,500,000 30,000,000 7,500,000 Basic and diluted net income (loss) per share $ (0.01 ) $ (0.01 ) $ 0.13 $ 0.13 Income Taxes The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the condensed financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of March 31, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with federal income tax regulations, income taxes are not levied on the Company, but rather on the individual owners. United States (“U.S.”) taxation would occur on the individual owners if certain tax elections are made by U.S. owners and the Company were treated as a passive foreign investment company. Additionally, U.S. taxation could occur to the Company itself if the Company is engaged in a U.S. trade or business. The Company is not expected to be treated as engaged in a U.S. trade or business at this time. Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of March 31, 2023. The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

Initial Public Offering

Initial Public Offering	3 Months Ended
	Mar. 31, 2023
Initial Public Offering [Abstract]
INITIAL PUBLIC OFFERING	NOTE 3. INITIAL PUBLIC OFFERING On February 17, 2021, the Company sold 30,000,000 Units, including the issuance of 2,500,000 Units as a result of the underwriters’ partial exercise of the over-allotment, at a purchase price of $10.00 per Unit. The over-allotment option covering an additional 1,625,000 units was expired on March 28, 2021. Each Unit consists of one Class A ordinary share, and one-third of one warrant to purchase one Class A ordinary share. Each whole warrant will entitle the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Each whole warrant will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO, February 17, 2021, and will expire five years after the completion of the initial Business Combination, or earlier upon redemption or liquidation. Following the closing of the IPO on February 17, 2021, an amount of $300,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in the Trust Account and was invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act that invests only in direct U.S. government treasury obligations. Warrants As of March 31, 2023, there were 10,000,000 public warrants and 5,333,333 private placement warrants outstanding ( not including the 285,409 warrants that could be issued upon conversion of the Convertible Promissory Notes) The warrants will become exercisable on the later of 12 months from the closing of the IPO or 30 days after the completion of its initial Business Combination, and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that, if the Company’s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but the Company will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00. Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon not less than 30 days’ prior written notice of redemption to each warrant holder; and ● if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders. Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00. Once the warrants become exercisable, the Company may redeem the outstanding warrants: ● in whole and not in part; ● at a price of $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the “fair market value” of the Company’s Class A ordinary shares; ● if, and only if, the closing price of the Company’s Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and ● if the closing price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants. The warrant agreement contains an Alternative Issuance provision that if less than 70% of the consideration receivable by the holders of the ordinary shares in the Business Combination is payable in the form of ordinary shares in the successor entity, and if the holders of the warrants properly exercise the warrants within thirty days following the public disclosure of the consummation of Business Combination by the Company, the warrant price shall be reduced by an amount equal to the difference (but in no event less than zero) of (i) the warrant price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of the Business Combination based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets. “Per Share Consideration” means (i) if the consideration paid to holders of the ordinary shares consists exclusively of cash, the amount of such cash per ordinary share, and (ii) in all other cases, the volume weighted average price of the ordinary shares as reported during the ten-trading day period ending on the trading day prior to the effective date of the Business Combination. The Company believes that the adjustments to the exercise price of the warrants is based on a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under FASB ASC Topic No. 815–40, and thus the warrants are not eligible for an exception from derivative accounting. The accounting treatment of derivative financial instruments requires that the Company record a derivative liability at fair value upon the closing of the IPO. The warrants were allocated a portion of the proceeds from the issuance of the Units equal to their fair value determined by the Monte Carlo simulation. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. If no events occurred during the period, the warrants will not be reclassified. The fair value of the liabilities is re-measured at the end of every reporting period and the change in fair value is reported in the statements of operations as a gain or loss on derivative financial instruments.

Private Placement

Private Placement	3 Months Ended
	Mar. 31, 2023
Private Placement [Abstract]
PRIVATE PLACEMENT	NOTE 4. PRIVATE PLACEMENT Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 5,333,333 Private Placement Warrants at a purchase price of $1.50 per Private Placement Warrant, generating gross proceeds to the Company of $8,000,000. The fair value of the warrants as of the Initial Public Offering was $1.38 per warrant, for a total initial fair value of $7,375,280. The excess of cash received over the fair value of the Private Placement Warrants was $624,720 and was reflected in additional paid-in capital on the statements of changes in shareholders’ equity (deficit) for the three months ended March 31, 2021. The proceeds from the sale of the Private Placement Warrants were added to the proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will not be redeemable by the Company so long as they are held by the Sponsor or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the warrants included in the units being sold in the IPO.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares On December 28, 2020, the Sponsor paid $25,000, or approximately $0.003 per share, to cover certain offering costs in consideration for 7,187,500 Class B ordinary shares, par value $0.0001. On February 11, 2021, the Company effected a share capitalization resulting in the sponsor holding an additional 718,750 class B ordinary shares for an aggregate of 7,906,250 class B ordinary shares including up to 1,031,250 Founder Shares subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option was exercised. On February 17, 2021, the underwriters partially exercised their over-allotment option, hence, 625,000 Founder Shares were no longer subject to forfeiture. At March 28, 2021, the over-allotment option expired, hence the 406,250 Class B ordinary shares were forfeited. As of March 31, 2023 and December 31, 2022, there were 7,500,000 Founder Shares issued and outstanding. The initial shareholders have agreed not to transfer, assign or sell any of their Founder Shares and any Class A ordinary shares issuable upon conversion thereof until the earlier to occur of: (i) one year after the completion of the initial Business Combination, or (ii) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after the initial Business Combination that results in all of the Company’s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property; except to certain permitted transferees and under certain circumstances (the “lock-up”). Notwithstanding the foregoing, if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination or (2) if the Company consummates a transaction after the initial Business Combination which results in the Company’s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the lock-up. Due to related party As of March 31, 2023 and December 31, 2022, the amount due to related party was $155,625 and $125,625, respectively, which represents the unpaid portion of the administrative service fee described below. Promissory Notes-Related Party On December 28, 2020, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company was allocated to borrow up to $300,000 to be used for a portion of the expenses of the IPO. These loans were non-interest bearing, unsecured and were due at the earlier of September 30, 2021 or the closing of the IPO. On February 22, 2021, the Company repaid $131,259 of amounts borrowed from the Sponsor, the funds of which were used to pay offering costs. The note was terminated at February 22, 2021. On February 14, 2023, the Company issued an unsecured convertible promissory note (the “Extension Note”, together with the “Working Capital Loans” as described below, called “Convertible Promissory Notes”) to the Sponsor, pursuant to which the Company may borrow up to $900,000 (the “Extension Loan”) from the Sponsor. Pursuant to the Extension Note, from February 17, 2023 to February 17, 2024 or such earlier date as is determined by the Company’s board of directors (such date, the “Extended Date”), the Sponsor has agreed to deposit into the Company’s trust account established in connection with its IPO the lesser of (i) $75,000 or (ii) $0.0375 for each unredeemed public share, for each month (or a pro rata portion thereof if less than a month) until the earlier of (i) the date of the extraordinary general meeting held in connection with a shareholder vote to approve an initial Business Combination, and (ii) the date that $900,000 has been loaned. Such loan may, at the Sponsor’s discretion, be converted into warrants (the “Extension Loan Warrants”) to purchase Class A ordinary shares of the Company, par value $0.0001 per share, at a conversion price equal to $1.50 per warrant, with each warrant entitling the holder to purchase one Class A ordinary share of the Company at a price of $11.50 per share, subject to the same adjustments applicable to the Private Placement Warrants in connection with the IPO of the Company’s securities. The terms of the Extension Loan Warrants will be identical to those of the Private Placement Warrants. The Extension Loan will not bear any interest, and will be repayable by the Company to the Sponsor, on a date that is the earlier of (a) the consummation of the Company’s initial merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities and (b) the liquidation of the Company. The maturity date of the Extension Loan may be accelerated upon the occurrence of an Event of Default (as defined under the Extension Note). The Extension Note was valued using the fair value method, with the changes of fair value at each reporting period recorded in the unaudited condensed statement of operations. As of March 31, 2023, $150,000 was drawn under the Extension Loan, with an initial fair value of $57,810 at the drawn down dates. The difference of $92,190, between the withdraws of $150,000 and the fair value at the drawn down dates of $57,810, was recorded in additional paid-in capital in the accompanying condensed statement of shareholder’s deficit for the three months ended March 31, 2023. As of March 31, 2023, the Extension Note was presented at its fair value of $58,044 on the accompanying condensed balance sheet (see Note 7). Up to the date that the condensed financial statements were issued, the Company had received $450,000 for the extension deposits under the Extension Note (see Note 10). For the three months ended March 31, 2023, the Company recorded $234 unrealized loss on fair value changes of the Extension Note in the accompanying unaudited condensed statement of operations. Working Capital Loans In addition, in order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company would repay the Working Capital Loans. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. A portion of the Working Capital Loans, not to exceed $1,500,000, may be convertible into Private Placement Warrants at a price of $1.50 per warrant at the option of the lender. Such warrants would be identical to the Private Placement Warrants. On December 13, 2022, the Company issued an unsecured convertible promissory note under the Working Capital Loan to the Sponsor, pursuant to which the Company may borrow up to $1,500,000 from the Sponsor (the “$1.5 Million Convertible Promissory Note”, together with the “Extension Note” as described above, the “Convertible Promissory Notes”). Such loan may, at the Sponsor’s discretion, be converted into Private Placement Warrants at a price of $1.50 per warrant as described above. The $1.5 Million Convertible Promissory Note will not bear any interest, and will be repayable by the Company to the Sponsor, on a date that is the earlier of (a) the consummation of the Company’s initial merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities and (b) the liquidation of the Company. The maturity date of the $1.5 Million Convertible Promissory Note may be accelerated upon the occurrence of an Event of Default (as defined under the $1.5 Million Convertible Promissory Note). As of March 31, 2023 and December 31, 2022, $278,564 and $0 were outstanding under the $1.5 Million Convertible Promissory Note. Up to the date that the condensed financial statements were issued, the Company received a total of $578,564 for working capital purposes under the $1.5 Million Convertible Promissory Note. The $1.5 Million Convertible Promissory Note was valued using the fair value method, with the changes of fair value at each reporting period recorded in statement of operations. As of March 31, 2023, $278,564 was drawn down under such loan, with an initial fair value of $107,128 at the drawn down date. The difference of $171,436, between the draw of $278,564 and the fair value at the drawn down dates of $107,128, was recorded in additional paid-in capital in the accompanying unaudited condensed statement of shareholder’s deficit. As of March 31, 2023, the $1.5 Million Convertible Promissory Note was presented at its fair value of $107,795 on the accompanying condensed balance sheets. As of December 31, 2022, the Company had no borrowings under the $1.5 Million Convertible Promissory Note. (See Note 7). For the three months ended March 31, 2023, the Company recorded $667 unrealized loss on fair value changes of the $1.5 Million Convertible Promissory Note in the accompanying unaudited condensed statement of operations. Administrative Service Fee The Company has agreed, commencing on the date the securities of the Company are first listed on NYSE, to pay the Sponsor $10,000 per month for office space, utilities, secretarial and administrative support services provided to members of the Company’s management team. For both the three months ended March 31, 2023 and 2022, the Company incurred $30,000 in expenses in connection with such services. All such expenses were recorded in the accompanying unaudited condensed statements of operations. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees.

Capital Contribution Note

Capital Contribution Note	3 Months Ended
	Mar. 31, 2023
Capital Contribution Note Abstract
Capital Contribution Note	Note 6. Capital Contribution Note On March 9, 2023 the Company entered into a subscription agreement (the “Subscription Agreement”) with the Sponsor and Polar Multi-Strategy Master Fund (the “Investor” or “Polar”), pursuant to which, the Sponsor is seeking to raise $1,200,000 to fund the Extension and to provide working capital to the Company. The Sponsor has committed to fund $900,000 of this amount through the Extension Note described in Note 5 above and the Investor has agreed to provide the remaining $300,000 (the “Capital Contribution Note”). The Company will request funds from the Sponsor for working capital purposes (“Drawdown Request”). Upon at least five (5) calendar days’ prior written notice (“Capital Notice”), the Sponsor may require a drawdown against the capital commitment in order to meet 25% of the Sponsor’s commitment to the Company under a Drawdown Request (“Capital Call”). In consideration of the Capital Call(s) made hereunder, the Company will issue 300,000 shares of Class A Common Stock to the Investor at the closing of a Business Combination. Any amounts funded by the Sponsor to the Company under a Drawdown Request shall not accrue interest and shall be promptly repaid by the the Company to the Sponsor upon the Business Combination Closing. Following receipt of such sums from the Company, and in any event within 5 business days of the Business Combination Closing, the Sponsor or the Company shall pay to the Investor, an amount equal to all amounts outstanding under the Subscription Agreement (the “Business Combination Payment”). The Company and Sponsor are jointly and severally obligated to make the Business Combination Payment to the Investor. The Investor may elect at the Business Combination Closing to receive such Business Combination Payment in cash or shares of Class A Common Stock at a rate of one share of Class A Common Stock for each $10 of the Capital Calls funded under this agreement. If the Company liquidates without consummating a Business Combination, any amounts remaining in the Sponsor or the Company’s cash accounts after paying any outstanding third party invoices (excluding any due to the Sponsor), not including the Company’s Trust Account, will be paid to the Investor within five (5) days of the liquidation. The Company treated the Capital Contribution Note as a debt instrument and measured it with fair value method, and records changes of fair value at each reporting period in the statement of operations. The fair value of the Capital Contribution Note will include both the fair value of the 300,000 shares in consideration for the Capital Calls and the principal as of each reporting date. As of March 31, 2023, $200,000 was drawn down under the Capital Contribution Note. The initial fair value of the Capital Contribution Note was $1,304,618. The difference of $1,104,618, between the $200,000 principal and the initial fair value of $1,304,618, was recorded as expenses in the accompanying unaudited condensed statement of operations for the three months ended March 31, 2023. As of March 31, 2023, the Capital Contribution Note was presented at its fair value of $1,308,748 on the accompanying condensed balance sheets (See Note 7). On May 24, 2023, the Company received the remaining $100,000 from Polar. Up to the date that the condensed financial statements were issued, the Company received $300,000 in total from Polar. For the three months ended March 31, 2023, the Company recorded $1,104,618 unrealized loss on excess of fair value of Capital Contribution Note over proceeds at issuance in the accompanying unaudited condensed statement of operations. For the three months ended March 31, 2023, the Company recorded $4,130 unrealized loss on fair value changes of the Capital Contribution Note in the accompanying unaudited condensed statement of operations.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 7. FAIR VALUE MEASUREMENTS The following tables presents information about the Company’s assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. March 31, Quoted Prices Significant Significant Liabilities Warrant Liability - Public Warrants $ 110,000 $ — $ 110,000 $ — Warrant Liability - Private Warrants 71,169 — 71,169 — Working Capital Loan 107,795 — — 107,795 Promissory Note- Related Party 58,044 — — 58,044 Promissory Note- Third Party 1,308,748 — — 1,308,748 Total $ 1,655,756 $ — $ 181,169 $ 1,474,587 December 31, Quoted Prices Significant Significant Assets Cash and investments held in Trust Account - Trading Securities $ 304,086,289 $ 304,086,289 $ — $ — $ 304,086,289 $ 304,086,289 $ — $ — Liabilities Warrant Liability - Public Warrants $ 42,000 $ 42,000 $ — $ — Warrant Liability - Private Warrants 26,660 — 26,660 — $ 68,660 $ 42,000 $ 26,660 $ — The Warrants, Working Capital Loan, Extension Notes and Capital Contribution Note are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities, Working Capital Loan, Promissory Note-Related Party and Capital Contribution Note, respectively, in the accompanying condensed balance sheets. The warrant liabilities, Working Capital Loan, Promissory Note-Related Party and Capital Contribution Note are measured at fair value at inception and on a recurring basis, with changes in fair value presented in the unaudited condensed statements of operations. The excess of proceeds over fair value at issuance was recorded as additional paid-in capital in the accompanying unaudited condensed statements of shareholders’ equity. The excess of fair value over proceeds at issuance was recorded as expenses in the accompanying unaudited condensed statement of operations. Warrant Liability The Company’s public and private warrant liabilities were valued using a Monte Carlo simulation at issuance date utilizing management judgment and pricing inputs from the quoted underlying ordinary shares. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the public and private warrant liabilities was initially classified as level 3. On November 4, 2022, the New York Stock Exchange (the “NYSE”) notified the Company, and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants, each whole warrant exercisable for one Class A ordinary share and listed to trade on NYSE under the symbol “CHAA WS”, from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The public warrants began to trade over-the counter (OTC) since then. On March 23, 2023, the Company received approval to transfer the listing of Class A ordinary shares from the NYSE to the NYSE American and on March 28, 2023, the Class A ordinary shares began trading on the NYSE American under the symbol “CHAA”. In connection with the transfer, effective March 28, 2023, any remaining units were mandatorily separated into their component parts and the units are no longer traded on the NYSE. The Company’s public warrants began trading under the ticker CHAAWS, on April 5, 2021. After this date, the public warrant values per share were based on the observed trading prices of the public warrants as of each balance sheet date. The fair value of the public warrant liability is classified as level 1 since April 5, 2021 and as of December 31, 2022. As of March 31, 2023, the fair value of the public warrant liability is re-classified as level 2 due to the insufficient trading volume. As of March 31, 2023 and December 31, 2022, the private placement warrant were valued using a Monte Carlo model using the quoted underlying public warrants. Due to the observable inputs in the fair value estimation of the Private warrants, these inputs were classified as level 2 as of December 31, 2022 and March 31, 2023. The key inputs used in the Monte Carlo simulation for the private warrants as of March 31, 2023 and December 31, 2022 were as follows: Input March 31, December 31, Public Warrant Price 0.011 0.004 Risk-free interest rate 4.44 % 4.74 % Expected term (years) 1.34 0.76 Expected volatility 3.1 % 5.4 % Stock price $ 10.26 $ 10.09 Exercise price $ 11.50 $ 11.50 Likelihood of Completing a Business Combination 40 % 50 % Convertible Promissory Notes Valuation of the convertible promissory notes (including the Extension Note and Working Capital Loan) was determined using a discounted cash flow analysis based on the estimated timing of the initial business combination and classified as a Level 3 valuation. The Key inputs for discounted cash flow analysis at initial draw dates and March 31, 2023 were as follows: Input March 31, 2023 Initial Draw Risk-free interest rate for warrant 3.6 % 3.73-4.17 % Risk-free interest rate for debt 4.82 % 4.83-5.09 % Term of Debt Conversion 0.7 0.73-0.80 Term of Warrant Conversion 5.7 5.73-5.80 Expected volatility 3.1 % 2.5-4.1 % Iterated/Market Stock price $ 10.26 $ 10.20-10.30 Exercise price of Warrants $ 11.5 $ 11.5 Strike Price of Debt Conversion $ 1.5 $ 1.5 Likelihood of Completing a Business Combination 40 % 40 % Activity for the three months ended March 31, 2023 for the convertible promissory notes (including the Extension Note and Working Capital Loan) was as follows: Extension Note Working Capital Proceeds from Convertible Promissory Notes $ 150,000 $ 278,564 Excess of proceeds over fair value at issuance (92,190 ) (171,436 ) Change in fair value through March 31, 2023 234 667 Fair value as of March 31, 2023 $ 58,044 $ 107,795 Capital Contribution Note Valuation of Capital Contribution Note was determined using a Probability Weighted Expected Return Method (“PWERM”) and classified as a Level 3 valuation. The PWERM is a multistep process in which value is estimated based on the probability -weighted present value of various future outcomes. The Key inputs for PWERM at at initial withdraw date and March 31, 2023 were as follows: Input March 31, Initial Draw Risk-free interest 4.8 % 4.6 % Estimated Term 0.7 0.72 Expected volatility 3.1 % 3.4 % Iterated/Market Stock price $ 10.26 $ 10.23 Likelihood of Completing a Business Combination 40 % 40 % Consideration for the Capital Call(s)- in shares 300,000 300,000 For the three months ended March 31, 2023, the activity in the Capital Contribution Note was as follows: Polar Proceeds from Capital Contribution Note $ 200,000 Excess of fair value over proceeds at issuance 1,104,618 Change in fair value through March 31, 2023 4,130 Fair value of the Capital Contribution Note as of March 31, 2023 $ 1,308,748

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8. COMMITMENTS AND CONTINGENCIES Registration Rights The holders of the Founder Shares, Class A shares that will be issued to Polar at Business Combination Closing, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans and Extension Note (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and Extension Note) will be entitled to registration rights pursuant to a registration and shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable Lock-up period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriters Agreement The underwriters are entitled to a deferred underwriting fee of 3.5% of the gross proceeds of the IPO, or $10,500,000, held in the Trust Account upon the completion of the Company’s initial Business Combination subject to the terms of the underwriting agreement. The deferred underwriting fee is included as a liability on the condensed balance sheets as of March 31, 2023 and December 31, 2022. On August 10, 2023, J.P. Morgan waived its entitlement to the payment of $10,500,000 deferred underwriting fee in connection with its role as underwriter in the Company’s IPO. Furthermore, J.P. Morgan had no role in connection with the business combination transaction. Advisory Agreements On March 14, 2023, the Company entered into an agreement with Chardan Capital Markets, LLC (“Chardan”) with respect to an event of a stock exchange demand for action by the Company (“Interim Listing Project”) at a time other than the initial closing of a business combination involving the Company and a target or targets. The agreement calls for Chardan to receive a fee of $175,000 at the signing of the agreement, a fee of $175,000 no later than 10 calendar days after Chardan informs the Company of the documented completion of the technical advisory activities and a deferred fee of $275,000 at the earlier of (i) the closing of the Transaction from the closing flow-of-funds or (ii) upon the liquidation of the trust account if the Company has not consummated a business combination. For the three months ended March 31, 2023, the Company recorded all of the $625,000 such advisory service fee in the accompanying unaudited condensed statement of operations. As of March 31, 2023, the Company has paid $175,000 to Chardan and the total unpaid amounts to Chardan was $450,000. Up to the date that the condensed financial statements were issued, the Company has paid $350,000 to Chardan and the total unpaid amounts to Chardan was $275,000. On March 26, 2023, the Company entered an agreement with Alumia SARL (“Alumnia”) to act as a non-exclusive transactional and strategic capital markets advisor to the Company assisting introductions and with respect to the Company’s potential business combination. The agreement calls for Alumnia to receive simultaneously with the closing of the Business Combination (a) a fee in the amount of $2,500,000 and (b) a fee of 4% multiplied by the dollar amount of the PIPE provided by third party investors identified and introduced by Alumnia, regardless of whether the counterparty in the applicable business combination was a subject target, payable upon the closing. Alumia is currently not involved in the Company’s Business Combination transaction with Crown, and no fee is currently payable under this agreement. On May 18, 2023, the Company engaged J.V.B. Financial Group, LLC, acting through its Cohen & Company Capital Markets division (“CCM”), to act as its (i) capital markets advisor in connection with a possible business combination transaction with Crown LNG (the “Target”) (such transaction, the “Sale Transaction”) and (ii) placement agent in connection with a private placement of equity, equity-linked, convertible and/or debt securities (the “Securities”) or other capital or debt raising transaction (the “Offering”, and, together with the Sale Transaction, each a “Transaction” and collectively the “Transactions”) in connection with the Sale Transaction. The Company shall pay CCM (i) an advisor fee in connection with the Sale Transaction in an amount equal to the sum of (I) $2,000,000 paid in full in U.S. dollars simultaneously with the closing of the Sale Transaction and (II) 50,000 shares of common stock or equivalent equity (the “Shares”) of the publicly listed post-business combination company (collectively, the “Advisor Fee”) and (ii) a transaction fee in connection with the Offering of an amount equal to 7.0% of the sum of (A) the gross proceeds raised from investors and received by the Company or Crown simultaneously with or before the closing of the Offering plus (B) proceeds released from the Trust Account with respect to any shareholder of the Company that (x) entered into a non-redemption or other similar agreement or (y) did not redeem the Company’s Class A ordinary shares, in each instance to the extent such investor or shareholder under (A) and (B) above was identified to the Company by CCM (the “Offering Fee” and together with the Advisor Fee, the “Transaction Fee”), which shall be payable in U.S. dollars by the Company and due to CCM simultaneously with the closing of the Offering. The Shares shall be fully duly authorized, validly issued, paid and non-assessable and shall be registered for resale under the Act, or otherwise freely tradeable, as of the closing of the Sale Transaction and will be delivered in book entry form in the name of and delivered to CCM (or its designee) at the closing of the Sale Transaction.

Shareholders_ Deficit

Shareholders’ Deficit	3 Months Ended
	Mar. 31, 2023
Shareholder's Deficit [Abstract]
SHAREHOLDERS’ DEFICIT	NOTE 9. SHAREHOLDERS’ DEFICIT Preference shares The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of March 31, 2023 and December 31, 2022, there were no preference shares issued or outstanding. Class A ordinary shares The Company is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. At March 31, 2023 and December 31, 2022, there were no Class B ordinary shares The Company is authorized to issue a total of 50,000,000 Class B ordinary shares at par value of $0.0001 per share. At March 31, 2023 and December 31, 2022, there were 7,500,000 Class B ordinary shares issued and outstanding. Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s second amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders. The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have redemption rights or be entitled to liquidating distributions from the Trust Account if the Company does not consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon the completion of the IPO, plus (ii) the total number of Class A ordinary shares issued, deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued or to be issued to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any member of the Company’s management team upon conversion of Working Capital Loans, unless the holders of a majority of the then-outstanding Class B ordinary shares agree to waive such adjustment with respect to such issuance or deemed issuance at the time thereof. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the condensed balance sheet date up to the date that the condensed financial statements were issued. Other than described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. Debt Financing for Extension Funds and Working Capital Subsequent to the condensed balance sheet date up to the date that the condensed financial statements were issued, the Company received $300,000 under each of the Working Capital Loan and Extension Note, for an aggregate of $600,000. On April 19, 2023, May 19, 2023, June 20, 2023 and July 20, 2023, the Company deposited four additional tranches of $75,000, for an aggregate of $300,000 into the Trust Account, to extend the date the Company has to consummate a business combination to August 17, 2023. The Company has 3 business days after August 17, 2023 to deposit another $75,000 to the Trust Account, to extend the date that the Company has to consummate a business combination to September 17, 2023. The Company will make such deposit shortly after the condensed financial statements are issued. On May 24, 2023, the Company received the remaining $100,000 from Polar. Up to the date that the condensed financial statements were issued, the Company received $300,000 in total from Polar. Business Combination Agreement On May 18, 2023, the Company engaged CCM, to act as its capital markets advisor and placement agent in connection with a possible business combination transaction with Crown as discussed in Note 1, Business Combination Agreement. Waiver of Deferred Underwriting Fees On August 10, 2023, J.P. Morgan waived its entitlement to the payment of $10,500,000 deferred underwriting fees in connection with its role as underwriter in the Company’s IPO. Furthermore, J.P. Morgan had no role in connection with the business combination transaction.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the period presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on April 24, 2023, which the accompanying condensed balance sheet as of December 31, 2022 was derived from. The interim results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply on on-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of the condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $115,597 and $20,706 in cash and did not have any cash equivalents as of March 31, 2023 and December 31, 2022, respectively.
Cash and investments held in Trust Account	Cash and investments held in Trust Account In March 2023, the Company liquidated the money market funds held in the Trust Account. The funds in the Trust Account will be maintained in cash in an interest-bearing demand deposit account at a bank until the earlier of consummation of the initial Business Combination and liquidation. Prior to liquidating the money market funds, the Company’s portfolio of investments was comprised primarily of U.S. Treasury securities. The Company classifies its money market funds as trading securities in accordance with ASC Topic 320, “Investments-Debt and Equity Securities.” Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from Trust Account in the accompanying unaudited condensed statements of operations. As of March 31, 2023 and December 31, 2023, the assets held in the Trust Account were $23,276,408 and $304,086,289, respectively.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At March 31, 2023 and December 31, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value Measurements	Fair Value Measurements FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”) defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: ● Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. ● Level 2 - Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. ● Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value of certain of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, approximates the carrying amounts represented in the condensed balance sheets. The fair values of prepaid expenses, accounts payable and accrued expenses, and due to related party are estimated to approximate the carrying values as of March 31, 2023 and December 31, 2022 due to the short maturities of such instruments.
Offering Costs Associated with IPO	Offering Costs Associated with IPO The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A-“Expenses of Offering”. Offering costs consist principally of underwriting fees, professional and registration fees that are related to the IPO. FASB ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between Class A ordinary shares and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then the Class A ordinary shares. Offering costs in the aggregate of $16,236,137 have been charged to shareholders’ equity (deficit) (consisting of $5,724,193 in underwriting fees, plus $10,017,338 in deferred underwriting fees, and $494,606 of other offering costs), offering costs in the aggregate of $795,046 have been recorded as other income (loss) (consisting of $275,807 in underwriting fees, plus $482,662 in deferred underwriting fees, and $36,577 of other offering costs) during the three months ended March 31, 2021.
Over-allotment Option Liability	Over-allotment Option Liability The Company accounted for the over-allotment option in accordance with the guidance contained in ASC 815-40. The over-allotment is not considered indexed to the Company’s own ordinary shares, and as such, it does not meet the criteria for equity treatment and is recorded as liabilities. On February 17, 2021, the underwriters exercised the over-allotment option partially and the remaining was expired on March 28, 2021. The fair value changes of over-allotment option liability between IPO closing date and the expiration date were recorded in operations during the year ended December 31, 2021.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in FASB ASC Topic 480, “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, all ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s condensed balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. In connection with the Extraordinary General Meeting held on February 14, 2023, holders of 27,785,141 Class A ordinary shares of the Company properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.18 per share, for an aggregate redemption amount of $282,903,643, which includes interest of $5,052,233. At March 31, 2023 and December 31, 2022, the Class A ordinary shares reflected in the condensed balance sheets are reconciled in the following table: Shares Amount Gross proceeds from initial public offering 30,000,000 $ 300,000,000 Less: Proceeds allocated to Public Warrants - (13,790,354 ) Less: Class A ordinary shares issuance costs - (16,236,137 ) Less: Initial fair value of over-allotment option - (325,679 ) Add: Remeasurement of Class A ordinary shares to redemption value - 30,352,170 Add: Accretion of interest income to Class A shares subject to redemption - 4,086,289 Class A ordinary shares subject to possible redemption as of December 31, 2022 30,000,000 304,086,289 Add: Accretion of interest income to Class A shares subject to redemption - 1,943,762 Add: Accretion of extension deposit to Class A shares subject to redemption - 150,000 Less: Class A shares redeemed, including interest (27,785,141 ) (282,903,643 ) Class A ordinary shares subject to possible redemption as of March 31, 2023 2,214,859 $ 23,276,408
Convertible Promissory Notes	Convertible Promissory Notes The Company elected to account for the Convertible Promissory Notes (which include the $1.5 million Convertible Promissory Note and the Extension Note) entered into with Catcha Holdings LLC (“Sponsor”) pursuant to the fair value option under ASC 825. ASC 825-10-15-4 provides for the “fair value option” (“FVO”) election, to the extent not otherwise prohibited by ASC 825-10-15-5, to be afforded to financial instruments, wherein the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Differences between the face value of the convertible promissory note and fair value at issuance are recognized as either an expense in the statement of operations (if issued at a premium) or as a capital contribution (if issued at a discount). Any material changes in the estimated fair value of the convertible promissory note are recognized as non-cash gains or losses in the condensed statements of operations. The Company believes that the fair value option better reflects the underlying economics of the Convertible Promissory Notes. As such, the Convertible Promissory Notes, were initially measured at $164,938 as of the issue date (including $107,128 under $1.5 Million Convertible Promissory Note and $57,810 under the Extension Note). The $263,626 excess of proceeds over fair value at issuance was recorded as additional paid-in capital in the accompanying unaudited condensed statements of shareholders’ deficit for the three months ended March 31, 2023. As of March 31, 2023, the fair value of the Convertible Promissory Notes was $165,839 (including $107,795 under $1.5 Million Convertible Promissory Note and $58,044 under the Extension Note). For the three months ended March 31, 2023, the Company recognized $901 unrealized loss on fair value changes of the Convertible Promissory Notes, in the unaudited condensed statement of operations.
Capital Contribution Note	Capital Contribution Note The Company elected to account for the Capital Contribution Note entered into with Polar Multi-Strategy Master Fund (“Investor”) and Catcha Holdings LLC (“Sponsor”) pursuant to the fair value option under ASC 825. ASC 825-10-15-4 provides for the “fair value option” (“FVO”) election, to the extent not otherwise prohibited by ASC 825-10-15-5, to be afforded to financial instruments, wherein the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Differences between the face value of the Capital Contribution Note and fair value at issuance are recognized as either an expense in the statement of operations (if issued at a premium) or as a capital contribution (if issued at a discount). Any material changes in the estimated fair value of the Capital Contribution Note are recognized as non-cash gains or losses in the condensed statements of operations. The Company believes that the fair value option better reflects the underlying economics of the Capital Contribution Note. The fair value of the Capital Contribution Note will include both the fair value of the 300,000 shares in consideration for the Capital Calls as defined in Note 6 and the principal as of each reporting date. As such, the Capital Contribution Note, was initially measured at $1,304,618 as of the issue date. The $1,104,618 excess of fair value of Capital Contribution Note over proceeds at issuance was recorded in the accompanying unaudited condensed statement of operations for the three months ended March 31, 2023. As of March 31, 2023, the fair value of the Capital Contribution Note was $1,308,748. For the three months ended March 31, 2023, the Company recognized $4,130 unrealized loss on fair value changes of the Capital Contribution Note, in the unaudited condensed statements of operations.
Warrant Liability	Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the warrants issued in connection with the IPO and the Private Placement in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classified each warrant as a liability at its fair value. This liability is subject to re-measurement at each reporting periods. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. As of March 31, 2023 and December 31, 2022, there were 15,333,333 public and private warrants outstanding (not including the 285,409 warrants that could be issued upon conversion of the Convertible Promissory Notes).
Net Income (Loss) Per Share	Net Income (Loss) Per Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 15,333,333 potential common shares for outstanding warrants to purchase the Company’s stock, the 285,709 potential common shares for the warrants that could be issued upon conversion of the Convertible Promissory Notes, to purchase the Company’s stock, and the 320,000 potential common shares (including 20,000 shares for the Business Combination Payment if Polar elects so and 300,000 shares in consideration of the Capital Calls as described in Note 6) that will be issued to Polar at Business Combination closing were excluded from diluted earnings per share for the three months ended March 31, 2023 and 2022 because the warrants and the shares that will be issued to Polar are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods. In addition, any shares subject to forfeiture are not included in weighted average shares outstanding until the forfeiture restrictions lapse. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares. Because the redemption value of the Class A ordinary shares approximates their fair value, remeasurement to redemption value is not impacting allocable earnings. For the Three Months Ended March 31, 2023 2022 Class A Class B Class A Class B Basic and diluted net income per share: Numerator: Allocation of net income (loss) $ (130,024 ) $ (58,307 ) $ 3,772,600 $ 943,150 Denominator: Weighted-average shares outstanding 16,724,877 7,500,000 30,000,000 7,500,000 Basic and diluted net income (loss) per share $ (0.01 ) $ (0.01 ) $ 0.13 $ 0.13
Income Taxes	Income Taxes The Company accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the condensed financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of March 31, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with federal income tax regulations, income taxes are not levied on the Company, but rather on the individual owners. United States (“U.S.”) taxation would occur on the individual owners if certain tax elections are made by U.S. owners and the Company were treated as a passive foreign investment company. Additionally, U.S. taxation could occur to the Company itself if the Company is engaged in a U.S. trade or business. The Company is not expected to be treated as engaged in a U.S. trade or business at this time.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective January 1, 2024 for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. The Company has not adopted this guidance as of March 31, 2023. The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Class A Ordinary Shares Reflected in the Condensed Balance Sheets	At March 31, 2023 and December 31, 2022, the Class A ordinary shares reflected in the condensed balance sheets are reconciled in the following table: Shares Amount Gross proceeds from initial public offering 30,000,000 $ 300,000,000 Less: Proceeds allocated to Public Warrants - (13,790,354 ) Less: Class A ordinary shares issuance costs - (16,236,137 ) Less: Initial fair value of over-allotment option - (325,679 ) Add: Remeasurement of Class A ordinary shares to redemption value - 30,352,170 Add: Accretion of interest income to Class A shares subject to redemption - 4,086,289 Class A ordinary shares subject to possible redemption as of December 31, 2022 30,000,000 304,086,289 Add: Accretion of interest income to Class A shares subject to redemption - 1,943,762 Add: Accretion of extension deposit to Class A shares subject to redemption - 150,000 Less: Class A shares redeemed, including interest (27,785,141 ) (282,903,643 ) Class A ordinary shares subject to possible redemption as of March 31, 2023 2,214,859 $ 23,276,408
Schedule of Basic and Diluted Net Income (Loss) Per Share for Each Class of Ordinary Shares	The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares. Because the redemption value of the Class A ordinary shares approximates their fair value, remeasurement to redemption value is not impacting allocable earnings. For the Three Months Ended March 31, 2023 2022 Class A Class B Class A Class B Basic and diluted net income per share: Numerator: Allocation of net income (loss) $ (130,024 ) $ (58,307 ) $ 3,772,600 $ 943,150 Denominator: Weighted-average shares outstanding 16,724,877 7,500,000 30,000,000 7,500,000 Basic and diluted net income (loss) per share $ (0.01 ) $ (0.01 ) $ 0.13 $ 0.13

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Measurements [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	March 31, Quoted Prices Significant Significant Liabilities Warrant Liability - Public Warrants $ 110,000 $ — $ 110,000 $ — Warrant Liability - Private Warrants 71,169 — 71,169 — Working Capital Loan 107,795 — — 107,795 Promissory Note- Related Party 58,044 — — 58,044 Promissory Note- Third Party 1,308,748 — — 1,308,748 Total $ 1,655,756 $ — $ 181,169 $ 1,474,587 December 31, Quoted Prices Significant Significant Assets Cash and investments held in Trust Account - Trading Securities $ 304,086,289 $ 304,086,289 $ — $ — $ 304,086,289 $ 304,086,289 $ — $ — Liabilities Warrant Liability - Public Warrants $ 42,000 $ 42,000 $ — $ — Warrant Liability - Private Warrants 26,660 — 26,660 — $ 68,660 $ 42,000 $ 26,660 $ —
Schedule of Monte Carlo Simulation for the Private Warrants	Input March 31, December 31, Public Warrant Price 0.011 0.004 Risk-free interest rate 4.44 % 4.74 % Expected term (years) 1.34 0.76 Expected volatility 3.1 % 5.4 % Stock price $ 10.26 $ 10.09 Exercise price $ 11.50 $ 11.50 Likelihood of Completing a Business Combination 40 % 50 %
Schedule of Discounted Cash Flow Analysis at Initial Withdraw Dates	Input March 31, 2023 Initial Draw Risk-free interest rate for warrant 3.6 % 3.73-4.17 % Risk-free interest rate for debt 4.82 % 4.83-5.09 % Term of Debt Conversion 0.7 0.73-0.80 Term of Warrant Conversion 5.7 5.73-5.80 Expected volatility 3.1 % 2.5-4.1 % Iterated/Market Stock price $ 10.26 $ 10.20-10.30 Exercise price of Warrants $ 11.5 $ 11.5 Strike Price of Debt Conversion $ 1.5 $ 1.5 Likelihood of Completing a Business Combination 40 % 40 %
Schedule of Convertible Promissory Notes	Extension Note Working Capital Proceeds from Convertible Promissory Notes $ 150,000 $ 278,564 Excess of proceeds over fair value at issuance (92,190 ) (171,436 ) Change in fair value through March 31, 2023 234 667 Fair value as of March 31, 2023 $ 58,044 $ 107,795
Schedule of Discounted Cash Flow Analysis	Input March 31, Initial Draw Risk-free interest 4.8 % 4.6 % Estimated Term 0.7 0.72 Expected volatility 3.1 % 3.4 % Iterated/Market Stock price $ 10.26 $ 10.23 Likelihood of Completing a Business Combination 40 % 40 % Consideration for the Capital Call(s)- in shares 300,000 300,000
Schedule of Capital Contribution Note	Polar Proceeds from Capital Contribution Note $ 200,000 Excess of fair value over proceeds at issuance 1,104,618 Change in fair value through March 31, 2023 4,130 Fair value of the Capital Contribution Note as of March 31, 2023 $ 1,308,748

Organization and Business Ope_2

Organization and Business Operation (Details) - USD ($)

1 Months Ended

3 Months Ended

Mar. 09, 2023

Feb. 17, 2021

Feb. 17, 2024

Feb. 14, 2023

Mar. 31, 2023

Mar. 31, 2021

Aug. 17, 2023

Aug. 10, 2023

Jul. 20, 2023

Jun. 20, 2023

May 24, 2023

May 19, 2023

Apr. 19, 2023

Mar. 21, 2023

Mar. 14, 2023

Feb. 22, 2023

Dec. 31, 2022

Organization and Business Operation (Details) [Line Items]

Issuance of units (in Shares)

2,500,000

Price per share (in Dollars per share)

$ 10

$ 10

Gross proceeds

$ 300,000,000

Class A ordinary shares (in Shares)

1

Price of per share (in Dollars per share)

$ 10

$ 10

Expire term

5 years

Aggregate warrant (in Shares)

15,333,333

285,409

Closing amount

$ 300,000,000

Debt maturity days

185 days

Cost amount

$ 17,031,183

Underwriting fees

6,000,000

Deferred underwriting fees

10,500,000

Other offering cost

$ 531,183

Transaction cost

$ 17,031,183

Additional paid in capital

16,236,137

Warrants

$ 795,046

Deferred underwriting fee

$ 175,000

Percentage of assets held in the trust account

80%

Interest to pay dissolution

$ 100,000

Redemption price

10.18%

Aggregate redemption amount

$ 282,903,643

Aggregate cost

$ 6

Company deposited tranches

$ 75,000

Trust account deposit

$ 75,000

Monthly deposits

$ 75,000

Public per share (in Dollars per share)

$ 10

Transaction value

$ 600,000,000

Description of business combination agreement

the seven years following the consumption of the Business Combination (the “Closing”), the persons who are Crown shareholders immediately prior to the Exchange Effective Time and who have participated in the Exchange (the “Exchanging Shareholders”) shall have the contingent right to receive in the aggregate a number of shares of PubCo Common Stock equivalent to 10% of the issued and outstanding PubCo Common Stock as of the Closing, which will vest upon achievement of certain share prices and milestones as provided under the Business Combination Agreement.

Cash

$ 115,597

$ 20,706

Working capital deficit

2,576,445

Borrow up amount

$ 1,200,000

$ 900,000

1,500,000

Outstanding loan amount

278,564

Working capital amount

578,564

Convertible promissory note

$ 1,500,000

Business combination, description

Pursuant to the Extension Note, from February 17, 2023 to February 17, 2024 or such earlier date as is determined by the Company’s board of directors (such date, the “Extended Date”), the Sponsor has agreed to deposit into the Company’s Trust Account established in connection with its IPO the lesser of (i) $75,000 or (ii) $0.0375 for each unredeemed public share, for each month (or a pro rata portion thereof if less than a month) until the earlier of (i) the date of the extraordinary general meeting held in connection with a shareholder vote to approve an initial Business Combination, and (ii) the date that $900,000 has been loaned. As of March 31, 2023, the Company has $150,000 outstanding under such loan. Up to the date that the condensed financial statements were issued, the Company had received $450,000 under the Extension Loan. Using these loans received, the Company deposited six tranches of $75,000 into Trust Account on February 22, 2023, March 21, 2023, April 19, 2023, May 19, 2023, June 20, 2023 and July 20, 2023, to extend the date that the Company has to consummate a business combination from February 17, 2023 to August 17, 2023.

Investment

$ 300,000

Loan outstanding

$ 200,000

Received amount

300,000

$ 100,000

Maximum [Member]

Organization and Business Operation (Details) [Line Items]

Company deposited tranches

$ 75,000

Minimum [Member]

Organization and Business Operation (Details) [Line Items]

Company deposited tranches

$ 450,000

Initial Public Offering [Member]

Organization and Business Operation (Details) [Line Items]

Units of initial public offer (in Shares)

30,000,000

Borrow up amount

$ 175,000

Private Placement Warrants [Member]

Organization and Business Operation (Details) [Line Items]

Price per share (in Dollars per share)

$ 1.5

Aggregate warrant (in Shares)

5,333,333

Private Placement [Member]

Organization and Business Operation (Details) [Line Items]

Gross proceeds

$ 8,000,000

Price of per warrant (in Dollars per share)

$ 1.5

Sponsor [Member]

Organization and Business Operation (Details) [Line Items]

Public per share (in Dollars per share)

10

Class A Ordinary Shares [Member]

Organization and Business Operation (Details) [Line Items]

Class A ordinary shares (in Shares)

1

Price of per share (in Dollars per share)

$ 11.5

$ 9.2

Holders shares (in Shares)

27,785,141

Class A Ordinary Shares [Member] | Warrant [Member]

Organization and Business Operation (Details) [Line Items]

Class A ordinary shares (in Shares)

1

Investment [Member]

Organization and Business Operation (Details) [Line Items]

Ownership interest

50%

Subsequent Event [Member]

Organization and Business Operation (Details) [Line Items]

Company deposited tranches

$ 75,000

$ 75,000

Monthly deposits

$ 75,000

Forecast [Member]

Organization and Business Operation (Details) [Line Items]

Deferred underwriting fee

$ 10,500,000

Company deposited tranches

75,000

$ 75,000

$ 75,000

Sponsor [Member]

Organization and Business Operation (Details) [Line Items]

Trust account deposit

$ 75,000

Business Combination [Member]

Organization and Business Operation (Details) [Line Items]

Public shares percentage

100%

Sponsor [Member]

Organization and Business Operation (Details) [Line Items]

Convertible promissory note

$ 1,500,000

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($)		3 Months Ended
	Feb. 14, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Significant Accounting Policies [Line Items]
Cash		$ 115,597		$ 20,706
Trust account investments		23,276,408		$ 304,086,289
Cash insured with federal deposit insurance		250,000
Interest amount	$ 5,052,233
Convertible promissory notes		$ 1,500,000
Convertible promissory notes, description		Convertible Promissory Notes, were initially measured at $164,938 as of the issue date (including $107,128 under $1.5 Million Convertible Promissory Note and $57,810 under the Extension Note). The $263,626 excess of proceeds over fair value at issuance was recorded as additional paid-in capital in the accompanying unaudited condensed statements of shareholders’ deficit for the three months ended March 31, 2023. As of March 31, 2023, the fair value of the Convertible Promissory Notes was $165,839 (including $107,795 under $1.5 Million Convertible Promissory Note and $58,044 under the Extension Note). For the three months ended March 31, 2023, the Company recognized $901 unrealized loss on fair value changes of the Convertible Promissory Notes, in the unaudited condensed statement of operations.
Unrealized loss		$ 901
Shares consideration (in Shares)		300,000
Capital Contribution Note measured amount		$ 1,304,618
Excess of fair value		1,104,618
Capital contribution note		1,308,748
Unrealized loss on fair value		$ 4,130
Class of warrants outstanding (in Shares)		15,333,333		285,409
Stock of common shares (in Shares)		320,000
shares of consideration (in Shares)		300,000
Offering Cost [Member]
Significant Accounting Policies [Line Items]
Offering costs in aggregate		$ 16,236,137
Adjustments to additional paid in capital underwriting fees		5,724,193
Adjustments to additional paid in capital deferred underwriting fee		10,017,338
Adjustments to additional paid in capital other offering costs		$ 494,606
Warrants [Member]
Significant Accounting Policies [Line Items]
Common shares for outstanding warrants (in Shares)		15,333,333	285,709
Class A Ordinary Shares [Member]
Significant Accounting Policies [Line Items]
Shares issued (in Shares)	27,785,141
Issued, per share (in Dollars per share)	$ 10.18
Redemption premium	$ 282,903,643
Operating Expense [Member] | IPO [Member]
Significant Accounting Policies [Line Items]
Transaction costs incurred in connection with IPO		$ 795,046
Underwriting fees		275,807
Deferred underwriting fees recognized		482,662
Other offering costs		$ 36,577
Business Combination [Member]
Significant Accounting Policies [Line Items]
Stock of common shares (in Shares)		20,000

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Class A Ordinary Shares Reflected in the Condensed Balance Sheets - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Schedule of Class A Ordinary Shares Reflected in the Condensed Balance Sheets [Abstract]
Gross proceeds from initial public offering (in Shares)		30,000,000
Gross proceeds from initial public offering		$ 300,000,000
Less: Proceeds allocated to Public Warrants		(13,790,354)
Less: Class A ordinary shares issuance costs		(16,236,137)
Less: Initial fair value of over-allotment option		(325,679)
Add: Remeasurement of Class A ordinary shares to redemption value		30,352,170
Add: Accretion of interest income to Class A shares subject to redemption	$ 1,943,762	$ 4,086,289
Class A ordinary shares subject to possible redemption (in Shares)	2,214,859	30,000,000
Class A ordinary shares subject to possible redemption	$ 23,276,408	$ 304,086,289
Add; Accretion of extension deposit to Class A shares subject to redemption	$ 150,000
Less: Class A shares redeemed, including interest (in Shares)	(27,785,141)
Less: Class A shares redeemed, including interest	$ (282,903,643)

Significant Accounting Polici_5

Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Share for Each Class of Ordinary Shares - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Class A [Member]
Numerator:
Allocation of net income (loss)	$ (130,024)	$ 3,772,600
Denominator:
Weighted-average shares outstanding	16,724,877	30,000,000
Basic and diluted net income (loss) per share	$ (0.01)	$ 0.13
Class B [Member]
Numerator:
Allocation of net income (loss)	$ (58,307)	$ 943,150
Denominator:
Weighted-average shares outstanding	7,500,000	7,500,000
Basic and diluted net income (loss) per share	$ (0.01)	$ 0.13

Significant Accounting Polici_6

Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Share for Each Class of Ordinary Shares (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Class A [Member]
Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Share for Each Class of Ordinary Shares (Parentheticals) [Line Items]
Diluted net income per share	$ 0.01	$ 0.13
Class B [Member]
Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Share for Each Class of Ordinary Shares (Parentheticals) [Line Items]
Diluted net income per share	$ 0.01	$ 0.13

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)			3 Months Ended
	Mar. 28, 2021	Feb. 17, 2021	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Initial Public Offering (Details) [Line Items]
Sale of stock issue price per share		$ 10	$ 10
Class of warrants or rights exercise price		$ 11.5
Warrants term		12 months
Class of warrants or rights maturity		5 years
Payment to acquire restricted investments (in Dollars)		$ 300,000,000
Restricted investments value per unit		$ 10
Maturity days		185 days
Warrants and rights outstanding (in Shares)			15,333,333	285,409
Share price		$ 10	$ 10
Percentage of aggregate gross proceeds			60%
Redemption trigger price per share			$ 18
Percentage of consideration received in form of ordinary shares			70%
Over-allotment option [Member]
Initial Public Offering (Details) [Line Items]
Additional shares (in Shares)	1,625,000
Common Stock [Member]
Initial Public Offering (Details) [Line Items]
Class of warrant or right, redemption price adjustment percentage			115%
Warrant [Member]
Initial Public Offering (Details) [Line Items]
Price per share			$ 18
Share Price More Than Or Equals To USD Eighteen [Member]
Initial Public Offering (Details) [Line Items]
Share price			$ 18
Number of consecutive trading days for determining share price			20 days
Class of warrants, redemption price per unit			$ 0.01
Share Price More Than Or Equals To USD Eighteen [Member] | Common Stock [Member]
Initial Public Offering (Details) [Line Items]
Class of warrant or right, redemption price adjustment percentage			180%
Share Price More Than Or Equals To USD Ten [Member]
Initial Public Offering (Details) [Line Items]
Share price			$ 10
Number of consecutive trading days for determining share price			20 days
Class of warrants, redemption price per unit			$ 0.1
Number of trading days for determining share price			30 days
Class A Ordinary Shares [Member]
Initial Public Offering (Details) [Line Items]
Class of warrants or rights exercise price			$ 11.5
Share price		$ 11.5	9.2
Price per share			18
Class A Ordinary Shares [Member] | IPO [Member]
Initial Public Offering (Details) [Line Items]
Payment to acquire restricted investments (in Shares)		30,000,000
Class A Ordinary Shares [Member] | Over-Allotment Option [Member]
Initial Public Offering (Details) [Line Items]
Payment to acquire restricted investments (in Shares)		2,500,000
Class A Ordinary Shares [Member] | Common Stock [Member]
Initial Public Offering (Details) [Line Items]
Share price			$ 9.2
Number of consecutive trading days for determining share price			20 days
Fair market value per share (in Shares)			0.361
Class A Ordinary Shares [Member] | Share Price More Than Or Equals To USD Ten [Member]
Initial Public Offering (Details) [Line Items]
Share price			$ 10
Number of consecutive trading days for determining share price			20 days
Number of trading days for determining share price			30 days
Public Warrants [Member]
Initial Public Offering (Details) [Line Items]
Warrants and rights outstanding (in Shares)			10,000,000
Private Placement Warrants [Member]
Initial Public Offering (Details) [Line Items]
Warrants and rights outstanding (in Shares)			5,333,333
Shares, Issued (in Shares)					285,409

Private Placement (Details)

Private Placement (Details) - Private Placement Warrants [Member]	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Private Placement (Details) [Line Items]
Aggregate purchased (in Shares) | shares	5,333,333
Purchase price per share (in Dollars per share) | $ / shares	$ 1.5
Gross proceeds from private placement	$ 8,000,000
Fair value of the warrant per share (in Dollars per share) | $ / shares	$ 1.38
Total initial fair value	$ 7,375,280
Cash received over the fair value	$ 624,720

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)			3 Months Ended	12 Months Ended
	Feb. 11, 2021	Dec. 28, 2020	Mar. 31, 2023	Dec. 31, 2022	Feb. 14, 2023	Dec. 13, 2022	Mar. 28, 2021	Feb. 22, 2021	Feb. 17, 2021
Related Party Transactions (Details) [Line Items]
Price per share (in Dollars per share)			$ 12
Founder shares issued (in Shares)			7,500,000	7,500,000
Founder shares outstanding (in Shares)			7,500,000	7,500,000
Due to related party			$ 155,625	$ 125,625
Borrowing amount						$ 1,500,000
Deposit to trust account					$ 75,000
Deposit price (in Dollars per share)					$ 0.0375
Warrants price per share (in Dollars per share)			$ 1.5			$ 1.5
Extension note, description			As of March 31, 2023, $150,000 was drawn under the Extension Loan, with an initial fair value of $57,810 at the drawn down dates. The difference of $92,190, between the withdraws of $150,000 and the fair value at the drawn down dates of $57,810, was recorded in additional paid-in capital in the accompanying condensed statement of shareholder’s deficit for the three months ended March 31, 2023. As of March 31, 2023, the Extension Note was presented at its fair value of $58,044 on the accompanying condensed balance sheet (see Note 7). Up to the date that the condensed financial statements were issued, the Company had received $450,000 for the extension deposits under the Extension Note (see Note 10).
Gain on fair value			$ 667
Working capital loans			1,500,000
Convertible promissory note amount			1,500,000			$ 1,500,000
Convertible promissory note not bear interest amount			1,500,000
Maturity date of convertible promissory note amount			1,500,000
Outstanding amount				$ 0		278,564
Working capital			$ 578,564
Convertible promissory note, description			The $1.5 Million Convertible Promissory Note was valued using the fair value method, with the changes of fair value at each reporting period recorded in statement of operations. As of March 31, 2023, $278,564 was drawn down under such loan, with an initial fair value of $107,128 at the drawn down date. The difference of $171,436, between the draw of $278,564 and the fair value at the drawn down dates of $107,128, was recorded in additional paid-in capital in the accompanying unaudited condensed statement of shareholder’s deficit. As of March 31, 2023, the $1.5 Million Convertible Promissory Note was presented at its fair value of $107,795 on the accompanying condensed balance sheets. As of December 31, 2022, the Company had no borrowings under the $1.5 Million Convertible Promissory Note. (See Note 7).
Unrealized loss on fair value changes			$ 1,500,000
Paid to sponsor			10,000
Incurred expenses			30,000
Over-Allotment Option [Member]
Related Party Transactions (Details) [Line Items]
Shares subject to forfeiture (in Shares)									625,000
Sponsor [Member]
Related Party Transactions (Details) [Line Items]
Borrowing amount		$ 300,000			$ 900,000			$ 131,259
Convertible promissory note amount						$ 1,500,000
Class B Ordinary Shares [Member]
Related Party Transactions (Details) [Line Items]
Sponsor paid		$ 25,000
Price per share (in Dollars per share)		$ 0.003
Ordinary shares (in Shares)	718,750	7,187,500
Ordinary shares, par value (in Dollars per share)		$ 0.0001
Aggregate shares (in Shares)	7,906,250
Shares subject to forfeiture (in Shares)	1,031,250
Class B Ordinary Shares [Member] | Over-Allotment Option [Member]
Related Party Transactions (Details) [Line Items]
Shares subject to forfeiture (in Shares)							406,250
Class A Ordinary Shares [Member]
Related Party Transactions (Details) [Line Items]
Price per share (in Dollars per share)					$ 11.5
Ordinary shares, par value (in Dollars per share)					0.0001
Warrants price per share (in Dollars per share)					$ 1.5
Working Capital Loan [Member]
Related Party Transactions (Details) [Line Items]
Convertible promissory note			1,500,000
Promissory Note Related Party [Member]
Related Party Transactions (Details) [Line Items]
Gain on fair value			$ 234
Business Combination [Member]
Related Party Transactions (Details) [Line Items]
Loan amount					$ 900,000

Capital Contribution Note (Deta

Capital Contribution Note (Details) - USD ($)		1 Months Ended	3 Months Ended
	Mar. 09, 2023	Mar. 24, 2023	Mar. 31, 2023	Mar. 31, 2022	Feb. 14, 2023
Capital Contribution Note (Details) [Line Items]
Fund extension amount	$ 1,200,000		$ 1,500,000		$ 900,000
Committed face amount	$ 900,000
Capital commitment percentage	25%
Fair value of capital contribution			300,000
Capital contribution note			$ 200,000
Initial capital contribution amount			$1,304,618
Withdrawal amount			$ 1,104,618
Withdrawal fair value amount			200,000
Fair value amount			1,304,618
Presented fair value amount			1,308,748
Received remaining amount		$ 100,000
Received total amount		$ 300,000
Unrealized loss on excess fair value			1,104,618
Unrealized loss on fair value			$ 4,130
Class A Ordinary Shares [Member]
Capital Contribution Note (Details) [Line Items]
Common stock issued per share (in Dollars per share)					$ 10.18
Capital Contribution Note [Member]
Capital Contribution Note (Details) [Line Items]
Committed face amount	$ 300,000
Capital Call [Member] | Class A Ordinary Shares [Member]
Capital Contribution Note (Details) [Line Items]
Common stock share issued (in Shares)	300,000
Common stock issued per share (in Dollars per share)	$ 10

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Total		$ 68,660
Total Assets		304,086,289
Held-to-Maturity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Cash and investments held in Trust Account - Cash		304,086,289
Public Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	$ 110,000	42,000
Private Placement Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	71,169	26,660
Working Capital Loan [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	107,795
Promissory Note Related Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	58,044
Promissory Note Third Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	1,308,748
Total	1,655,756
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Total		42,000
Total Assets		304,086,289
Fair Value, Inputs, Level 1 [Member] | Held-to-Maturity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Cash and investments held in Trust Account - Cash		304,086,289
Fair Value, Inputs, Level 1 [Member] | Public Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability		42,000
Fair Value, Inputs, Level 1 [Member] | Private Placement Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 1 [Member] | Working Capital Loan [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 1 [Member] | Promissory Note Related Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 1 [Member] | Promissory Note Third Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Total		26,660
Total Assets
Fair Value, Inputs, Level 2 [Member] | Held-to-Maturity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Cash and investments held in Trust Account - Cash
Fair Value, Inputs, Level 2 [Member] | Public Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	110,000
Fair Value, Inputs, Level 2 [Member] | Private Placement Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	71,169	26,660
Fair Value, Inputs, Level 2 [Member] | Working Capital Loan [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 2 [Member] | Promissory Note Related Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 2 [Member] | Promissory Note Third Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Total	181,169
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Total
Total Assets
Fair Value, Inputs, Level 3 [Member] | Held-to-Maturity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Cash and investments held in Trust Account - Cash
Fair Value, Inputs, Level 3 [Member] | Public Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 3 [Member] | Private Placement Warrants [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability
Fair Value, Inputs, Level 3 [Member] | Working Capital Loan [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	107,795
Fair Value, Inputs, Level 3 [Member] | Promissory Note Related Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	58,044
Fair Value, Inputs, Level 3 [Member] | Promissory Note Third Party [Member]
Fair Value Measurements (Details) - Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Warrant Liability	1,308,748
Total	$ 1,474,587

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of Monte Carlo Simulation for the Private Warrants - Private Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Public Warrant Price	$ 0.011	$ 0.004
Risk-free interest rate	4.44%	4.74%
Expected term (years)	1 year 4 months 2 days	9 months 3 days
Expected volatility	3.10%	5.40%
Stock price	$ 10.26	$ 10.09
Exercise price	$ 11.5	$ 11.5
Likelihood of Completing a Business Combination	40%	50%

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of Discounted Cash Flow Analysis at Initial Withdraw Dates - $ / shares	1 Months Ended	3 Months Ended
	Mar. 21, 2023	Mar. 31, 2023
Convertible Promissory Notes [Member]
Fair Value Measurements (Details) - Schedule of Discounted Cash Flow Analysis at Initial Withdraw Dates [Line Items]
Risk-free interest rate for warrant		3.60%
Risk-free interest rate for debt		4.82%
Term of Debt Conversion		8 months 12 days
Term of Warrant Conversion		5 years 8 months 12 days
Expected volatility		3.10%
Iterated/Market Stock price (in Dollars per share)		$ 10.26
Exercise price of Warrants (in Dollars per share)		11.5
Strike Price of Debt Conversion (in Dollars per share)		$ 1.5
Likelihood of Completing a Business Combination		40%
Initial Withdraw [Member]
Fair Value Measurements (Details) - Schedule of Discounted Cash Flow Analysis at Initial Withdraw Dates [Line Items]
Exercise price of Warrants (in Dollars per share)	$ 11.5
Strike Price of Debt Conversion (in Dollars per share)	$ 1.5
Likelihood of Completing a Business Combination	40%
Initial Withdraw [Member] | Minimum [Member]
Fair Value Measurements (Details) - Schedule of Discounted Cash Flow Analysis at Initial Withdraw Dates [Line Items]
Risk-free interest rate for warrant	3.73%
Risk-free interest rate for debt	4.83%
Term of Debt Conversion	8 months 23 days
Term of Warrant Conversion	5 years 8 months 23 days
Expected volatility	2.50%
Iterated/Market Stock price (in Dollars per share)	$ 10.2
Initial Withdraw [Member] | Maximum [Member]
Fair Value Measurements (Details) - Schedule of Discounted Cash Flow Analysis at Initial Withdraw Dates [Line Items]
Risk-free interest rate for warrant	4.17%
Risk-free interest rate for debt	5.09%
Term of Debt Conversion	9 months 18 days
Term of Warrant Conversion	5 years 9 months 18 days
Expected volatility	4.10%
Iterated/Market Stock price (in Dollars per share)	$ 10.3

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of Convertible Promissory Notes	3 Months Ended
	Mar. 31, 2023 USD ($)
Extension Note [Member]
Fair Value Measurements (Details) - Schedule of Convertible Promissory Notes [Line Items]
Proceeds from Convertible Promissory Notes	$ 150,000
Excess of proceeds over fair value at issuance	(92,190)
Change in fair value through March 31, 2023	234
Fair value as of March 31, 2023	58,044
Working Capital Loan [Member]
Fair Value Measurements (Details) - Schedule of Convertible Promissory Notes [Line Items]
Proceeds from Convertible Promissory Notes	278,564
Excess of proceeds over fair value at issuance	(171,436)
Change in fair value through March 31, 2023	667
Fair value as of March 31, 2023	$ 107,795

Fair Value Measurements (Deta_5

Fair Value Measurements (Details) - Schedule of Discounted Cash Flow Analysis - Capital Contribution Note [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk-free interest	4.80%
Estimated Term	8 months 12 days
Expected volatility	3.10%
Iterated/Market Stock price (in Dollars per share) | $ / shares	$ 10.26
Likelihood of Completing a Business Combination	40%
Consideration for the Capital Call(s)- in shares (in Shares) | shares	300,000
Initial Withdraw [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk-free interest	4.60%
Estimated Term	8 months 19 days
Expected volatility	3.40%
Iterated/Market Stock price (in Dollars per share) | $ / shares	$ 10.23
Likelihood of Completing a Business Combination	40%
Consideration for the Capital Call(s)- in shares (in Shares) | shares	300,000

Fair Value Measurements (Deta_6

Fair Value Measurements (Details) - Schedule of Capital Contribution Note - Polar [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Defined Contribution Plan Disclosure [Line Items]
Proceeds from Capital Contribution Note	$ 200,000
Excess of fair value over proceeds at issuance	1,104,618
Change in fair value through March 31, 2023	4,130
Fair value of the Capital Contribution Note as of March 31, 2023	$ 1,308,748

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)		1 Months Ended		3 Months Ended
	Mar. 14, 2023	May 18, 2023	Mar. 26, 2023	Mar. 31, 2023	Aug. 10, 2023	Mar. 09, 2023	Feb. 14, 2023	Dec. 31, 2022
Commitments and Contingencies (Details) [Line Items]
Gross proceeds				$ 10,500,000				$ 10,500,000
Agreement fee amount	$ 175,000
Fees amount	175,000		$ 2,500,000
Deferred fee	275,000
Advisory service fee				625,000
Paid amount				$ 1,500,000		$ 1,200,000	$ 900,000
Paid amount	$ 350,000
Fees percentage			4%
Sale of transaction amount		$ 2,000,000
Sale of transaction shares (in Shares)		50,000
Offering amount equal percentage		7%
IPO [Member]
Commitments and Contingencies (Details) [Line Items]
Deferred underwriting fee, percentage				3.50%
Gross proceeds				$ 10,500,000
Paid amount				175,000
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Unpaid amounts				450,000
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Unpaid amounts				$ 275,000
Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Agreement fee amount					$ 10,500,000
J.P. Morgan [Member] | Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Agreement fee amount					$ 10,500,000

Shareholders_ Deficit (Details)

Shareholders’ Deficit (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Shareholders’ Deficit (Details) [Line Items]
Preference shares authorized	5,000,000	5,000,000
Preference shares par value (in Dollars per share)	$ 0.0001	$ 0.0001
shares of consideration	300,000
Stock of common shares	320,000
Withdraw of the capital contribution (in Dollars)	$ 200,000
Aggregate percentage	20%
Class A Ordinary Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
Common stock shares authorized	500,000,000	500,000,000
Common stock, value per share (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock shares issued
Common stock shares outstanding
Ordinary shares subject to possible redemption	2,214,859	30,000,000
Class B Ordinary Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
Common stock shares authorized	50,000,000	50,000,000
Common stock, value per share (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock shares issued	7,500,000	7,500,000
Common stock shares outstanding	7,500,000	7,500,000
Business Combination [Member]
Shareholders’ Deficit (Details) [Line Items]
Stock of common shares	20,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)		1 Months Ended					3 Months Ended
	Aug. 10, 2023	Jul. 20, 2023	Jun. 20, 2023	May 24, 2023	May 19, 2023	Apr. 19, 2023	Mar. 31, 2023	Aug. 17, 2023	Feb. 22, 2023
Subsequent Events (Details) [Line Items]
Working capital loan							$ 300,000
Aggregate amount							$ 600,000
Deposit amount									$ 75,000
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Aggregate deposited trust account					$ 75,000	$ 75,000
Deposit amount					$ 75,000	$ 75,000
Received amount				$ 100,000
Forecast [Member]
Subsequent Events (Details) [Line Items]
Aggregate amount								$ 300,000
Aggregate deposited trust account		$ 75,000	$ 75,000
Deposit amount		$ 75,000	$ 75,000					$ 75,000
Payment of underwriting fees	$ 10,500,000
Polar [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Received amount				$ 300,000